Processa Pharmaceuticals (PCSA) Non-Current Deferred Tax Liability (2012 - 2021)

Processa Pharmaceuticals (PCSA) has reported Non-Current Deferred Tax Liability for 7 consecutive years, with $181752.0 the latest figure, recorded in Q3 2021.

• For the quarter ending Q3 2021, Non-Current Deferred Tax Liability fell 85.4% year-over-year to $181752.0; the trailing twelve-month figure through Sep 2021 stood at $181752.0 (down 85.4% YoY), and the FY2020 full-year result was $530611.0, down 65.36% from the prior year.
• Non-Current Deferred Tax Liability slipped to $181752.0 in Q3 2021 per PCSA's latest filing, from $304194.0 in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $2.5 million in Q2 2018 and bottomed at $181752.0 in Q3 2021.
• Historically, Non-Current Deferred Tax Liability has averaged $1.4 million across 4 years, with a median of $1.5 million in 2019.
• The sharpest annual moves came in 2019 and 2021: Non-Current Deferred Tax Liability declined 25.32% in 2019, then plunged 85.4% in 2021.
• Over 4 years, Non-Current Deferred Tax Liability stood at $2.1 million in 2018, then decreased by 28.24% to $1.5 million in 2019, then slumped by 65.36% to $530611.0 in 2020, then plunged by 65.75% to $181752.0 in 2021.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $181752.0, $304194.0, and $441363.0 for Q3 2021, Q2 2021, and Q1 2021 respectively.